BioNTech SE (NASDAQ:BNTX) shares rose 4.4% during trading on Thursday . The stock traded as high as $273.88 and last traded at $271.00. Approximately 16,905 shares changed hands during trading, a decline of 99% from the average daily volume of 2,197,576 shares. The stock had previously closed at $259.61.
Several research firms have recently weighed in on BNTX. Berenberg Bank set a $130.00 price target on BioNTech and gave the stock a “buy” rating in a research note on Tuesday, April 6th. JPMorgan Chase & Co. set a $104.00 target price on shares of BioNTech and gave the company a “neutral” rating in a research note on Tuesday, April 6th. Wolfe Research initiated coverage on shares of BioNTech in a research note on Monday. They issued an “outperform” rating and a $248.00 price target for the company. SVB Leerink restated a “hold” rating on shares of BioNTech in a research report on Wednesday, June 23rd. Finally, Redburn Partners reaffirmed a “sell” rating and issued a $146.00 target price on shares of BioNTech in a research report on Wednesday, June 16th. They noted that the move was a valuation call. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the company’s stock. BioNTech presently has an average rating of “Hold” and a consensus target price of $169.83.
The firm has a market cap of $66.49 billion, a price-to-earnings ratio of 45.47 and a beta of -1.58. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.70 and a quick ratio of 2.58. The business has a 50 day moving average of $217.35.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Compagnie Lombard Odier SCmA lifted its position in BioNTech by 959.1% during the second quarter. Compagnie Lombard Odier SCmA now owns 24,465 shares of the company’s stock valued at $5,469,000 after purchasing an additional 22,155 shares during the last quarter. Schroder Investment Management Group raised its position in BioNTech by 8.0% during the first quarter. Schroder Investment Management Group now owns 62,213 shares of the company’s stock valued at $6,793,000 after purchasing an additional 4,606 shares during the period. Optiver Holding B.V. purchased a new position in shares of BioNTech in the 1st quarter worth approximately $18,630,000. TownSquare Capital LLC bought a new position in shares of BioNTech during the 1st quarter valued at approximately $269,000. Finally, Bamco Inc. NY raised its holdings in BioNTech by 73.3% during the 1st quarter. Bamco Inc. NY now owns 252,977 shares of the company’s stock valued at $27,623,000 after buying an additional 107,014 shares during the period. Hedge funds and other institutional investors own 12.42% of the company’s stock.
BioNTech Company Profile (NASDAQ:BNTX)
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors.
See Also: What is the float in trading stocks?
Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.